EUVIMEDEUVIMED entdecken
EditorialKommentar

Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy

Eric A Meyerowitz iD

Clinical Infectious Diseases · 20.05.2026 · 82 (5) · e921-e922

DOI: 10.1093/cid/ciag164 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.03.2026. Verfasst von Eric A Meyerowitz. Beteiligte Einrichtung: Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NewYork, USA. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NewYork, USA.

ORCID-Profile: Eric A Meyerowitz

Zitieren

APA

Meyerowitz, E. A. (2026). Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy. Clinical Infectious Diseases, 82(5), e921-e922. https://doi.org/10.1093/cid/ciag164

Vancouver

Meyerowitz EA. Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy. Clinical Infectious Diseases. 2026;82(5):e921-e922. doi:10.1093/cid/ciag164

BibTeX
@article{Meyerowitz2026,
  author = {Meyerowitz, Eric A},
  title = {Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {5},
  pages = {e921--e922},
  doi = {10.1093/cid/ciag164}
}
Kostenlos starten →